This is a working overview of half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
telomere A region of repetitive nucleotide sequences at each end of a linear chromosome which protects the end of the chromosome from deterioration and from fusion with other chromosomes. Since each round of replication results in the shortening of the chromosome, telomeres act as disposable buffers which are sacrificed to perpetual truncation instead of nearby genes; telomeres can also be lengthened by the enzyme telomerase.
Recently, several studies have highlighted the prospect of using carbon nanotubes as building blocks to fabricate three-dimensional macroscopic (>100 nm in all three dimensions) all-carbon devices. Lalwani et al. have reported a novel radical-initiated thermal crosslinking method to fabricate macroscopic, free-standing, porous, all-carbon scaffolds using single- and multi-walled carbon nanotubes as building blocks. These scaffolds possess macro-, micro-, and nano-structured pores, and the porosity can be tailored for specific applications. These 3D all-carbon scaffolds/architectures may be used for the fabrication of the next generation of energy storage, supercapacitors, field emission transistors, high-performance catalysis, photovoltaics, and biomedical devices, implants, and sensors.
The downfall of the overall cyclol model generally led to a rejection of its elements; one notable exception was J. D. Bernal's short-lived acceptance of the Langmuir-Wrinch hypothesis that protein folding is driven by hydrophobic association. Nevertheless, cyclol bonds were identified in small, naturally occurring cyclic peptides in the 1950s. Clarification of the modern terminology is appropriate. The classic cyclol reaction is the addition of the NH amine of a peptide group to the C=O carbonyl group of another; the resulting compound is now called an azacyclol. By analogy, an oxacyclol is formed when an OH hydroxyl group is added to a peptidyl carbonyl group. Likewise, a thiacyclol is formed by adding an SH thiol moiety to a peptidyl carbonyl group. The oxacyclol alkaloid ergotamine from the fungus Claviceps purpurea was the first identified cyclol. The cyclic depsipeptide serratamolide is also formed by an oxacyclol reaction. Chemically analogous cyclic thiacyclols have also been obtained. Classic azacyclols have been observed in small molecules and tripeptides. Peptides are naturally produced from the reversion of azacylols, a key prediction of the cyclol model. Hundreds of cyclol molecules have now been identified, despite Linus Pauling's calculation that such molecules should not exist because of their unfavorably high energy. After a long hiatus during which she worked mainly on the mathematics of X-ray crystallography, Wrinch responded to these discoveries with renewed enthusiasm for the cyclol model and its relevance in biochemistry.
The most recently named elements – nihonium (113), moscovium (115), tennessine (117), and oganesson (118) – completed the seventh row of the periodic table. Future elements would have to begin an eighth row. These elements may be referred to either by their atomic numbers (e.g. "element 164"), or by the IUPAC systematic element names adopted in 1978, which directly relate to the atomic numbers (e.g. "unhexquadium" for element 164, derived from Latin unus "one", Greek hexa "six", Latin quadra "four", and the traditional -ium suffix for metallic elements). All attempts to synthesize such elements have failed so far. Attempts to make element 119 have been ongoing since 2018 at the Riken research institute in Japan and since 2026 at the JINR in Russia, and an attempt to make element 120 has been ongoing since 2025 at the LBNL in the United States. The Heavy Ion Research Facility in Lanzhou (HIRFL) in China also plans to make its own attempts at synthesizing the first few period 8 elements. If the eighth period followed the pattern set by the earlier periods, then it would contain fifty elements, filling the 8s, 5g, 6f, 7d, and finally 8p subshells in that order. But by this point, relativistic effects should result in significant deviations from the Madelung rule. Various different models have been suggested for the configurations of eighth-period elements, as well as how to show the results in a periodic table. All agree that the eighth period should begin like the previous ones with two 8s elements, 119 and 120.
Sources: en.wikipedia.org
Jung decided that his near-psychotic experiences were of value and, in private, he induced hallucinations or, in his words, a process of "active imagination". He recorded everything he experienced in small journals, which Jung referred to in the singular as his Black Book, considering it a "single integral whole", even though some of these original journals have a brown cover. Jung described his 1912 book as "an attempt, only partially successful, to create a wider setting for medical psychology and to bring the whole of the psychic phenomena within its purview". The book was later revised and retitled Symbols of Transformation in 1952. The material Jung wrote was subjected to several edits, hand-written and typed, including another, "second layer" of text, his continual psychological interpretations during the process of editing. Around 1915, Jung commissioned a large red leather-bound book, and began to transcribe his notes and paint, working intermittently for sixteen years. Jung left no posthumous instructions about the final disposition of what he called the Liber Novus or Red Book. Sonu Shamdasani, a historian of psychology from London, tried for three years to persuade Jung's resistant heirs to have it published. Ulrich Hoerni, Jung's grandson who manages the Jung archives, decided to publish it when the necessary additional funds were raised through the Philemon Foundation. Up to September 2008, fewer than about two dozen people had ever seen it. In 2007, two technicians for DigitalFusion, working with New York City publishers W. W.
== Career == In 1898, she founded the Philadelphia Clinical Laboratory and conducted bacteriological analyses. She educated farmers on the handling of raw milk in order to improve the safety of ice cream sold at local schools. In the same year, she accepted a position with the Women's Medical College of Pennsylvania as director of their clinical laboratory. She also served as a research worker in the department of hygiene at the University of Pennsylvania from 1898 to 1901, and was a bacteriologist with the Philadelphia Bureau of Health. In her position with the Bureau of Health, she was instrumental in improving sanitation standards for the handling of milk and milk products.
Dyson also did work in a variety of topics in mathematics, such as topology, analysis, number theory and random matrices. In 1973 the number theorist Hugh Lowell Montgomery was visiting the Institute for Advanced Study and had just made his pair correlation conjecture concerning the distribution of the zeros of the Riemann zeta function. He showed his formula to the mathematician Atle Selberg, who said that it looked like something in mathematical physics and that Montgomery should show it to Dyson, which he did. Dyson recognized the formula as the pair correlation function of the Gaussian unitary ensemble, which physicists have studied extensively. This suggested that there might be an unexpected connection between the distribution of primes (2, 3, 5, 7, 11, ...) and the energy levels in the nuclei of heavy elements such as uranium. Around 1979 Dyson worked with the Institute for Energy Analysis on climate studies. This group, under Alvin Weinberg's direction, pioneered multidisciplinary climate studies, including a strong biology group. Also during the 1970s, Dyson worked on climate studies conducted by the JASON defense advisory group. Dyson retired from the Institute for Advanced Study in 1994. In 1998 he joined the board of the Solar Electric Light Fund. In 2003 he was president of the Space Studies Institute, the space research organization founded by Gerard K. O'Neill; in 2013 he was on its board of trustees. Dyson was a longtime member of the JASON group. Dyson won numerous scientific awards, but never a Nobel Prize.
==== Clemency ==== In response to the Trump administration's crackdown on immigrants with criminal records, Newsom gave heightened consideration to people in this situation. A pardon can eliminate the grounds for deportation of immigrants who would otherwise be legal permanent residents. Pardon requests from people facing deportation are given expedited review by the state Board of Parole Hearings, per a 2018 California law. In his first acts of clemency as governor, Newsom pardoned seven formerly incarcerated people in May 2019, including two Cambodian refugees facing deportation. He pardoned three men who were attempting to avoid being deported to Cambodia or Vietnam in November 2019. They had separately committed crimes when they were each 19 years old. In December 2019, Newsom granted parole to a Cambodian refugee who had been held in a California prison due to a murder case. Although immigrant rights groups wanted Newsom to end policies allowing the transfer to federal agents, the refugee was turned over for possible deportation upon release. On January 13, 2022, Newsom denied parole to Sirhan Sirhan, Robert F. Kennedy's assassin, who had been recommended for parole by a parole board after serving 53 years in prison. Newsom wrote an op-ed for the Los Angeles Times saying Sirhan "still lacks the insight that would prevent him from making the kind of dangerous and destructive decisions he made in the past.
On 1 July 2025, Thailand's Constitutional Court ruled in a 7–2 vote to suspend Paetongtarn from her official duties. The decision followed a petition from 36 senators who accused her of dishonesty and ethical standards breaches during the phone call. The Senate petition, submitted on 20 June by Senate President Mongkol Surasajja, alleged Paetongtarn violated Sections 160 and 170 of the Thai Constitution by abusing her position and undermining national interest. The Constitutional Court subsequently accepted the case, giving her 15 days to submit a defence. Suriya Jungrungreangkit took over as the acting prime minister from 1 July 2025 to 3 July 2025. Afterwards the position was taken over by Phumtham Wechayachai. Phumtham included Paetongtarn in his interim cabinet as the culture minister. On August 29, 2025, the verdict led to Paetongtarn’s removal from office.
Sources: en.wikipedia.org
== Early life == Margaret Ruth Kidder, one of five children, was born on October 17, 1948, in Yellowknife, Northwest Territories, the daughter of Jocelyn Mary "Jill" (née Wilson), a history teacher from British Columbia, and Kendall Kidder, an American explosives expert and engineer originally from New Mexico. She was of Welsh and English descent. Kidder was born in Yellowknife because of her father's employment, which required the family to live in remote locations. Her father subsequently served as the manager of the Yellowknife Telephone Company from 1948 to 1951. She had one sister, Annie, who is an actress and executive director of the People for Education charity, and three brothers: John, Michael, and Peter. Two of her siblings married notable Canadians: Annie married actor Eric Peterson and John married politician Elizabeth May. Kidder's niece Janet Kidder is also an actress. Recalling her childhood in northern Canada, Kidder said: "We didn't have movies in this little mining town. When I was 12, my mom took me to New York [City] and I saw Bye Bye Birdie, with people singing and dancing, and that was it. I knew I had to go far away. I was clueless, but I [have done] okay." In addition to Yellowknife, she also spent some time growing up in Labrador City, Newfoundland and Labrador. Kidder became interested in politics at a young age, which she credited to debates which her parents had over the dinner table; her mother had socialist leanings, while her father was a conservative Republican.
These suppressor tRNA mutations also target stop codons that are not mutations, causing some proteins to be much longer than they should be. Only bacteria and lower eukaryotes can survive with these mutations, mammal and insect cells die as a result of a suppressor mutation. For historical reasons the three stop codons were given names (see Stop codons): UAG is called the amber codon, UAA is called the ochre codon, and UGA is called the opal codon.
In 1949, Glenn T. Seaborg, who devised the actinide concept, predicted that element 103 (lawrencium) should be the last actinide and that the Lr3+ ion should be about as stable as Lu3+ in aqueous solution. It was not until decades later that element 103 was finally conclusively synthesized and this prediction was experimentally confirmed. Studies on the element, performed in 1969, showed that lawrencium reacts with chlorine to form a product that was most likely the trichloride, LrCl3. Its volatility was found to be similar to the chlorides of curium, fermium, and nobelium and much less than that of rutherfordium chloride. In 1970, chemical studies were performed on 1500 atoms of 256Lr, comparing it with divalent (No, Ba, Ra), trivalent (Fm, Cf, Cm, Am, Ac), and tetravalent (Th, Pu) elements. It was found that lawrencium coextracted with the trivalent ions, but the short half-life of 256Lr precluded a confirmation that it eluted ahead of Md3+ in the elution sequence. Lawrencium occurs as the trivalent Lr3+ ion in aqueous solution and hence its compounds should be similar to those of the other trivalent actinides: for example, lawrencium(III) fluoride (LrF3) and hydroxide (Lr(OH)3) should both be insoluble in water. Due to the actinide contraction, the ionic radius of Lr3+ should be smaller than that of Md3+, and it should elute ahead of Md3+ when ammonium α-hydroxyisobutyrate (ammonium α-HIB) is used as an eluant.
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. Linagliptin is a dipeptidyl peptidase-4 inhibitor that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth. Common side effects include inflammation of the nose and throat. Serious side effects may include angioedema, pancreatitis, joint pain. Use in pregnancy and breastfeeding is not recommended. Linagliptin was approved for medical use in the United States, Japan, the European Union, Canada, and Australia in 2011. In 2023, it was the 254th most commonly prescribed medication in the United States, with more than 1 million prescriptions. From August 2021, linagliptin became available as a generic medicine in the US.
According to the Russian investigators, Yekaterina Kharebava noticed the movement of the Russian troops before the August 2008 War and reported this movement to the Georgian intelligence. In 2017, Russian president Vladimir Putin decreed to free another two women imprisoned for sending SMSes about the April 2008 Russian military deployment to Abkhazia. Kharebava and Sevastidi had already left the prison by that time.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.